Clinical Trial
Accepted on 12 Nov 2025
Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
in Cancer Immunity and Immunotherapy